Colleen Rivard1, Melissa Geller2, Erica Schnettler3, Manju Saluja3, Rachel Isaksson Vogel4, Ashok Saluja5, Sundaram Ramakrishnan3. 1. Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, USA. Electronic address: clrivard@umn.edu. 2. Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, USA. 3. Department of Pharmacology, University of Minnesota, USA. 4. Biostatistics and Bioinformatics, Masonic Cancer Center, University of Minnesota, USA. 5. Department of Surgery, University of Minnesota, USA.
Abstract
OBJECTIVE: Minnelide is a water-soluble pro-drug of triptolide, a natural product. The goal of this study was to evaluate the effectiveness of Minnelide on ovarian cancer growth in vitro and in vivo. METHODS: The effect of Minnelide on ovarian cancer cell proliferation was determined by real time electrical impedance measurements. Multiple mouse models with C200 and A2780 epithelial ovarian cancer cell lines were used to assess the efficacy of Minnelide in inhibiting ovarian cancer growth. RESULTS: Minnelide decreased cell viability of both platinum sensitive and resistant epithelial ovarian cancer cells in vitro. Minnelide with carboplatin showed additive effects in vitro. Minnelide monotherapy increased the survival of mice bearing established ovarian tumors. Minnelide, in combination with carboplatin and paclitaxel, improved overall survival of mice. CONCLUSIONS: Minnelide is a promising pro-drug for the treatment of ovarian cancer, especially when combined with standard chemotherapy.
OBJECTIVE:Minnelide is a water-soluble pro-drug of triptolide, a natural product. The goal of this study was to evaluate the effectiveness of Minnelide on ovarian cancer growth in vitro and in vivo. METHODS: The effect of Minnelide on ovarian cancer cell proliferation was determined by real time electrical impedance measurements. Multiple mouse models with C200 and A2780 epithelial ovarian cancer cell lines were used to assess the efficacy of Minnelide in inhibiting ovarian cancer growth. RESULTS:Minnelide decreased cell viability of both platinum sensitive and resistant epithelial ovarian cancer cells in vitro. Minnelide with carboplatin showed additive effects in vitro. Minnelide monotherapy increased the survival of mice bearing established ovarian tumors. Minnelide, in combination with carboplatin and paclitaxel, improved overall survival of mice. CONCLUSIONS:Minnelide is a promising pro-drug for the treatment of ovarian cancer, especially when combined with standard chemotherapy.
Authors: Rohit Chugh; Veena Sangwan; Satish P Patil; Vikas Dudeja; Rajinder K Dawra; Sulagna Banerjee; Robert J Schumacher; Bruce R Blazar; Gunda I Georg; Selwyn M Vickers; Ashok K Saluja Journal: Sci Transl Med Date: 2012-10-17 Impact factor: 17.956
Authors: Phoebe A Phillips; Vikas Dudeja; Joshua A McCarroll; Daniel Borja-Cacho; Rajinder K Dawra; William E Grizzle; Selwyn M Vickers; Ashok K Saluja Journal: Cancer Res Date: 2007-10-01 Impact factor: 12.701
Authors: Veronika Auner; Gernot Kriegshäuser; Dan Tong; Reinhard Horvat; Alexander Reinthaller; Alexander Mustea; Robert Zeillinger Journal: BMC Cancer Date: 2009-04-09 Impact factor: 4.430
Authors: Vivek Ramakrishnan; Christopher de Haydu; Peter Wilkinson; Urvashi Hooda; Bhuwan Giri; Janneth M Oleas; Veronica Rive; Sabita Roy; Vikas Dudeja; Brian Slomovitch; Ashok Saluja; Sundaram Ramakrishnan Journal: Am J Cancer Res Date: 2021-05-15 Impact factor: 6.166
Authors: Satish Patil; Lev G Lis; Robert J Schumacher; Beverly J Norris; Monique L Morgan; Rebecca A D Cuellar; Bruce R Blazar; Raj Suryanarayanan; Vadim J Gurvich; Gunda I Georg Journal: J Med Chem Date: 2015-11-24 Impact factor: 7.446